NON-EXECUTIVE CHAIR RESIGNATION

Perth, Australia; 29 December 2025 - Argenica Therapeutics Limited (ASX: AGN) ("Argenica" or the "Company"), a biotechnology company developing novel therapeutics to reduce brain tissue death after stroke and other neurological conditions, advises that Ms Dianne Angus has notified the Board of her decision to step down as Non-Executive Chair and Director of the Company, effective end December.

Ms Angus has served on the Board since December 2023 and has been instrumental in guiding the Company through early-stage clinical development, in particular the successful Phase 2 clinical trial in acute ischaemic stroke and the strategic expansion of Argenica's therapeutic pipeline. Dianne's strong capabilities in governance have also seen her embed rigorous governance, risk management and compliance frameworks appropriate for a clinical-stage biotechnology company.

Dianne has worked tirelessly with the Board and management in positioning Argenica for its next phase of growth.

The Board extends its sincere thanks to Dianne for her significant contribution, leadership and commitment to Argenica during this foundational period, and wishes her every success in her future endeavours.

The Board has already commenced a process to appoint a new Chair with deep experience in global business development and strategic partnering to support Argenica's next stage of international growth. A further announcement regarding Chair succession will be made in due course.

Authorised for release by the Board and Company Secretary.

For more information please contact: info@argenica.com.au

ABOUT ARGENICA

Argenica (ASX: AGN) is developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. Our lead neuroprotective peptide candidate, ARG-007, has been successfully demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE). The Company has completed a Phase 1 clinical trial in healthy human volunteers to assess the safety and tolerability of a single dose of ARG-007. Argenica has recently completed a Phase 2 clinical trial in acute ischaemic stroke patients, as well as continuing to generate preclinical data in other neurological conditions.